I think PFE is the likely suitor or may be partner like Lipitor in 1996-98,before buyout.
BMY has spent a lot on Amylin and problematic Inhibitex..
SNY is a good candidate also.
The key question: Who can quickly exploit Vascepa sales worldwide?
Pfizer has demonstrated that they are a great marketing co.--not a good R&D co.
SNY is a great R&D co.-- as well as good marketing co.